12 October 2023
EMA/CHMP/449195/2023

# CHMP List of questions

To be addressed by the marketing authorisation holder for Ocaliva

Procedure under Article 20 of Regulation (EC) No 726/2004

Ocaliva EMEA/H/A-20/1531/C/004093/0045

Marketing authorisation holder: Advanz Pharma Limited

INN/active substance: Obeticholic acid

**Official address** Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
**Address for visits and deliveries** Refer to www.ema.europa.eu/how-to-find-us
**Send us a question** Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

The marketing authorisation holder (MAH) is requested to address the following questions:

Question 1

Provide information on the estimated patient exposure to obeticholic acid in the different European Economic Area Member States and worldwide. This should include a line listing/details of and data from ongoing and completed clinical studies, non-interventional studies and post-marketing sources; presented separately.

Data on the use in clinical practice including information on dose, duration of treatment and concomitant treatment (characterisation of users, prescriptions) and use in combination with ursodeoxycholic acid (UDCA) or as monotherapy (as included in Section 4.1 of the SmPC) should be provided, if available. Information on pattern of use of Ocaliva outside the recommendations provided in current SmPC should be presented as well.

Question 2

Provide all available efficacy data from studies 747-302 and 747-401. The MAH should discuss the results in the context of all available data (i.e. previously submitted data and any new data that were not submitted yet, e.g. from other (ongoing) clinical studies or published literature); this should include a discussion of any potential reasons for the discrepant results of study 747-302 and 747-401 compared to the data available at the time of the conditional marketing authorisation in terms of efficacy.

Question 3

Provide all available safety data from studies 747-302 and 747-401. The MAH should discuss the results in the context of all available data (i.e. previously submitted data and any new data that were not submitted yet, e.g. from other (ongoing) clinical studies or published literature). In particular a comprehensive summary and critical discussion is awaited on hepatic safety, renal safety, cardiovascular safety, gastrointestinal safety, as well as regarding fatigue, dyslipidaemia, cholelithiasis and pruritus events.

Question 4

Please provide a cumulative review of all spontaneous and solicited case reports of hepatic and gastrointestinal events (mostly, but not restricted, to advanced stage PBC), thrombotic and CV events, fatigue, dyslipidaemia, cholelithiasis, renal and pruritus events reported with Ocaliva as a suspected or interacting medicinal product received from the MAH’s safety database, literature and other available databases, e.g. EudraVigilance.

Question 5

Considering the above, provide a full benefit-risk balance evaluation of Ocaliva in the currently approved indication(s).